MoneyWorks4Me

Cohance Lifesciences informs about completion of USFDA inspection

05 Sep 2026 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cohance Lifesciences has informed that the United States Food and Drug Administration (USFDA) inspected the Company’s formulation (FDF) plant located at Shamshabad, Telangana, from 27 August to 4 September 2026. The inspection concluded with the issuance of a Form FDA 483 containing four observations. The Company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline. The Company remains committed to quality and regulatory compliance.

The above information is a part of company’s filings submitted to BSE.

Cohance Lifesciences Share Price

456.55 -3.60 (-0.78%)
04-Sep-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.00
Dr. Reddys Labs. 1154.00
Cipla 1385.00
Lupin 2111.00
Zydus Lifesciences 1121.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: